Areas of Focus:

Adaptive ImmunityAnimal ModelsBiological & MechanisticBiomarker DiscoveryCollaboration & InnovationCross-institutional CollaborationData-Driven & QuantitativeExperimental Platforms & ModelsImmune ProfilingImmune ToleranceIn Vitro ModelsMachine Learning & AISystems BiologyTherapeutic DevelopmentTranslational & ClinicalCross-Cutting & Special PopulationsEndocrine DiseasesMultiple SclerosisNeurologic DiseasesOverlap SyndromesRare Autoimmune DiseasesRheumatoid ArthritisSystemic DiseasesSystemic Lupus Erythematosus (SLE)Type 1 Diabetes
  • Professor, Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine / NYU Langone Health

Dr. Xiangpeng Kong is a Professor in the Department of Biochemistry and Molecular Pharmacology at NYU Grossman School of Medicine, where his laboratory sits at the interface of structural biology, protein engineering, and immunology. His research program is unified by a focus on immune recognition and checkpoint regulation — and on translating mechanistic insights into therapeutic strategies.

A central area of Dr. Kong’s work is structure-guided therapeutic development, encompassing HIV vaccine design, antibody structure-function analysis, and the development of PD-1 pathway agonist antibodies as a novel approach to treating autoimmune disease. To pursue these questions, his group employs an integrated toolkit of cryo-electron microscopy (cryo-EM), X-ray crystallography, and functional immune assays, enabling a detailed view of how immune molecules interact and how those interactions can be precisely modulated.

Projects

Featured Pilot Projects

Development of Rationally Designed PD-1 Agonist Biologics for the Treatment of Autoimmune Diseases
Project | New York University

Development of Rationally Designed PD-1 Agonist Biologics for the Treatment of Autoimmune Diseases

Exploiting a newly discovered PD-1 dimerization mechanism, this project engineers monoclonal antibodies to more effectively suppress overactive T cells — offering a novel immune tolerance strategy for autoimmune diseases.